{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Add an additional location for the clinical drug supply and distribution vendor.', 'Indicate that study medication vial assignments and volume of study drug to be', 'administered are obtained from an electronic data capture (EDC) system and not an', 'interactive web response system (IWRS).', 'Clarify that the weight obtained at Week 12 can be used for the calculation of study drug', 'dose beginning at Week 12 or Week 15.', 'Remove the specified temperature collection methods (oral or tympanic).', 'Add pharmacokinetic (PK) sampling pre- and post-infusion on Day 1, Week 3 and', 'Week 9 of the Treatment Period, with single samples collected at Weeks 1, 4 and 24.', 'Change the definition of the end of the trial to date of the last subject contact at', 'Month 24.', 'Update Sponsor Representative title.', 'Correct minor typographical errors (changes are not detailed below).', 'The following sections of the protocol are affected: 2, 2.1, Table 6.1, 7.1.3.4.5.5.1, 7.2, 8.1, 8.2,', '8.3, 9.1, Figure 9.1, 9.3.1, 9.3.2, 9.3.3, 9.3.4, 9.4.1, 9.4.6.2, 9.4.6.3.1, 9.4.6.3.2, 9.4.8, ,9.5.1,', '9.5.1.1, 9.5.1.2, 9.5.1.3, 9.5.2, 9.5.3, 9.5.4.1.2, 9.5.4.3, 9.5.4.4, 9.5.4.5, 9.5.4.7, 9.5.5, 9.5.6.1,', '9.5.6.2, 9.5.6.3, 9.5.6.4, 9.5.6.5, 9.5.6.6, 9.5.6.7, 9.5.6.8, 9.5.6.9, 9.5.6.10, 9.5.6.11, 9.5.6.12,', '9.5.6.13, 9.5.6.14.1, 9.5.6.14.2, 9.5.6.15.1, 9.5.6.15.2, 9.5.6.16, 9.6.1, 9.6.1.1, 9.6.1.2, 9.6.1.3,', '9.6.3, 9.6.3.2.1, and 17.1. Additional text is marked in red, underlined, and bolded; deleted text is', 'marked as strikethrough text.', '2', 'SYNOPSIS', 'Objectives:', 'Primary Objective', 'The primary objective is to evaluate the effect of teprotumumab on the proptosis responder rate', '(i.e., the percentage of subjects with a > 2 mm reduction from Baseline in the study eye without', 'deterioration 1> 2 mm increase of proptosis in the fellow eye) at Week 24the EOT Visit.', 'Secondary Objectives', 'Secondary objectives will evaluate the effect of teprotumumab on the following:', '1.', 'Percentage of subjects with a Clinical Activity Score (CAS) value of 0 or 1', 'at', 'Week 24the EOT Visit in the study eye.', '2.', 'Mean change from Baseline to Week 24 the EOT Visit in proptosis measurement in the', 'study eye.', '3.', 'Diplopia responder rate (i.e., the percentage of subjects with baseline diplopia > 0 in', 'study eye who have a reduction of > 1 grade with no corresponding deterioration', '1 grade worsening in the fellow eye) at Week 24.', '4.3.', \"Mean change from Baseline to Week 24the EOT Visit- in the Graves' Ophthalmopathy\", 'Quality of Life (GO-QoL) questionnaire overall score.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 6 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Exploratory Objectives', 'Exploratory objectives will evaluate the effect of teprotumumab on the following:', '1. The overall responder rate (percentage of subjects with > 2-point reduction in CAS AND', '> 2 mm reduction in proptosis from Baseline, provided there is no corresponding', 'deterioration 1> 2-point/mm increase] in CAS or proptosis in the fellow eye) at Week 24 the', 'EOT Visit.', '2. Clinical Measures of Severity individual response status frequencies and percentage of', 'responders for each component of clinical severity at Week 24 the EOT Visit.', '3. Mean change from Baseline to Week 24 the EOT Visit-in the CAS.', '4. Overall responder rate at Week 24 the EOT Visit-stratified by the level of response (high', 'responders, responders, low responders, and non-responders; see Section 9.6.3.2.1 for', 'definitions).', '5. Mean change from Baseline to Week 24 the EOT Visit-in the GO-QoL questionnaire visual', 'functioning (VF) and appearance (A) subscale scores.', '6. Mean change from Baseline to Week 24 the EOT Visit-on the motility component of the', 'Clinical Measures of Severity.', '7. Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure', 'and understand PK-PD relationships.', 'Study Design:', 'All subjects who choose to participate will receive up to 8 infusions of teprotumumab (10 mg/kg', 'for the first infusion followed by 20 mg/kg for the remaining 7 infusions) in an open-label', \"fashion., with the number of infusions determined by the Investigator' clinical judgment (but\", 'not to exceed 8 infusions)The Baseline (Day 1) Visit of this extension study will occur within', '14 days after the final visit of Study HZNP-TEP-301 (Week 24 for proptosis non-responders and', 'up to Week 72 for subjects who relapse). During the open-label Treatment Period, study drug', 'infusions are scheduled for Day 1 (Baseline), and Weeks 3, 6, 9, 12, 15, 18, and 21 (with a final', 'visit at Week 24 of the 24-Week Treatment Period). When the Investigator considers', 'treatment to be complete, subjects will have an End of Treatment (EOT) Visit 3 weeks after the', 'final nfusion and undergo the scheduled EOT assessments.', 'After completion of the Treatment Period, subjects who were proptosis non-responders in Study', 'HZNP-TEP-301 will enter a 24-week Follow-Up Period, during which study drug will not be', 'administered and clinic visits are scheduled for 1, 3, and 6 months (Visits Month 7, 9 and 12)', 'after the Week 24 EOT-Visit; if any of these subjects discontinue from the Follow-Up Period', 'prior to the Month 12 Visit, they will return to the clinic and undergo the scheduled Month 12', 'assessments prior to study discharge. Those who complete the Month 12 Visit will be', 'contacted 6 and 12 months later via phone or email by research staff to enquire if any', 'treatment for TED has been received since last study contact. If yes, subject will be', 'questioned regarding type of treatment and outcome/response.', 'Subjects who relapse during the Follow-Up Period of HZNP-TEP-301 and choose to enter this', 'extension study will not participate in the Follow-Up Period. For these subjects, the last clinic', 'visit is at Week 24. Those who complete the Week 24 Visit will be contacted 6 and', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 7 of 118']\n\n###\n\n", "completion": "END"}